| Ident. | Authors (with country if any) | Title |
|---|
| 001860 (2011) |
Andreas Kupsch [Allemagne] ; Michele Tagliati [États-Unis] ; Marie Vidailhet [France] ; Tipu Aziz [Royaume-Uni] ; Paul Krack [France] ; Elena Moro [Canada] ; Joachim K. Krauss [Allemagne] | Early postoperative management of DBS in dystonia: Programming, response to stimulation, adverse events, medication changes, evaluations, and troubleshooting |
| 001864 (2011) |
Alberto J. Espay [États-Unis] ; Joe P. Giuffrida [États-Unis] ; Robert Chen [Canada] ; Megan Payne [États-Unis] ; Filomena Mazzella [Canada] ; Emily Dunn [États-Unis] ; Jennifer E. Vaughan [États-Unis] ; Andrew P. Duker [États-Unis] ; Alok Sahay [États-Unis] ; Sang Jin Kim [Canada] ; Fredy J. Revilla [États-Unis] ; Dustin A. Heldman [États-Unis] | Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease |
| 002613 (2007) |
Valerie Voon [États-Unis, Canada] ; Susan Fox [Canada] ; Tracy R. Butler [États-Unis] ; Anthony E. Lang [Canada] | Antidepressants and psychosis in Parkinson disease: a case series |
| 002664 (2007) |
Valerie Voon [États-Unis, Canada] ; Susan H. Fox [Canada] | Medication-related impulse control and repetitive behaviors in parkinson disease |
| 002907 (2006) |
V. Voon [États-Unis, Canada] ; K. Hassan [Canada] ; M. Zurowski [Canada] ; S. Duff-Canning [Canada] ; M. De Souza [Canada] ; S. Fox [Canada] ; A. E. Lang [Canada] ; J. Miyasaki [Canada] | Prospective prevalence of pathologic gambling and medication association in Parkinson disease |
| 002932 (2006) |
Andrew R. Willan [Canada] ; Ron Goeree [Canada] ; Eleanor M. Pullenayegum [Canada] ; Christopher Mcburney [États-Unis] ; Gordon Blackhouse [Canada] | Economic evaluation of rivastigmine in patients with parkinson's disease dementia |
| 002B17 (2005) |
Guy Chouinard [Canada] ; Howard C. Margolese [Canada] | Manual for the Extrapyramidal Symptom Rating Scale (ESRS) |
| 002B48 (2005) |
Brad Hagen [Canada] ; Chris Armstrong Esther [Canada] ; Roland Ikuto [Canada] ; Robert J. Williams [Canada] ; Carole-Lynne Le Navenec [Canada] ; Morgan Aho | Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation |
| 002C90 (2004) |
Colleen P. Millikin [Canada] ; Lisa L. Trepanier [Canada] ; Sean B. Rourke [Canada] | Verbal fluency component analysis in adults with HIV/AIDS |
| 002E89 (2003) |
C. Warren Olanow [États-Unis] ; Christopher G. Goetz [États-Unis] ; Jeffrey H. Kordower [États-Unis] ; A. Jon Stoessl [Canada] ; Vesna Sossi [Canada] ; Mitchell F. Brin [États-Unis] ; Kathleen M. Shannon [États-Unis] ; G. Michael Nauert [États-Unis] ; Daniel P. Perl [États-Unis] ; James Godbold [États-Unis] ; Thomas B. Freeman [États-Unis] | A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease |
| 002E96 (2003) |
W. R. Wayne Martin [Canada] ; Marguerite Wieler [Canada] | Treatment of Parkinson's disease |
| 002E98 (2003) |
Pierre J. Blanchet [Canada] | The fluctuating Parkinsonian patient: Clinical and pathophysiological aspects |
| 002F05 (2003) |
Pierre J. Blanchet [États-Unis, Canada] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] | Renaissance of amantadine in the treatment of Parkinson's disease |
| 002F07 (2003) |
J. G. Nutt [États-Unis] ; K. J. Burchiel [États-Unis] ; C. L. Comella [États-Unis] ; Joseph Jankovic [États-Unis] ; A. E. Lang [Canada] ; E. R. Jr Laws [États-Unis] ; A. M. Lozano [Canada] ; R. D. Penn [États-Unis] ; R. K. Jr Simpson [États-Unis] ; M. Stacy [États-Unis] ; G. F. Wooten [États-Unis] | Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD |
| 002F11 (2003) |
Simon Lemay [Canada] ; Pierre Blanchet [Canada] ; Sylvain Chouinard [Canada] ; Hélène Masson [Canada] ; Valérie Soland [Canada] ; Marc-André Bedard [Canada] | Poor tolerability of a transdermal nicotine treatment in Parkinson's disease |
| 002F16 (2003) |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 002F18 (2003) |
A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable |
| 002F22 (2003) |
Ajit Kumar [Canada] ; ZHIGAO HUANG [Canada] ; Raul De La Fuente-Fernandez [Canada] | Mechanisms of motor complications in treatment of Parkinson's disease |
| 002F33 (2003) |
Yoshiaki Furukawa [Canada] | Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss |
| 002F43 (2003) |
Michael Iskedjian [Canada] ; Thomas R. Einarson [Canada] | Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease |
| 002F44 (2003) |
Pierre J. Blanchet [États-Unis, Canada] ; Spiros Konitsiotis [États-Unis, Grèce] ; Hideki Mochizuki [États-Unis, Japon] ; Ryszard Pluta [États-Unis] ; Dwaine F. Emerich [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis] | Complications of a trophic xenotransplant approach in parkinsonian monkeys |
